Gene sequencing company Illumina will pay $8 billion in cash and stock to buy cancer screening startup Grail, the companies said.
Gene sequencing company Illumina will pay $8 billion in cash and stock to buy cancer screening startup Grail, the companies said.
Comments are closed.